| Literature DB >> 31683835 |
Izabela N Faria Gomes1,2, Renato J Silva-Oliveira3, Viviane A Oliveira Silva4, Marcela N Rosa5, Patrik S Vital6, Maria Cristina S Barbosa7, Fábio Vieira Dos Santos8, João Gabriel M Junqueira9, Vanessa G P Severino10, Bruno G Oliveira11, Wanderson Romão12, Rui Manuel Reis13,14,15, Rosy Iara Maciel de Azambuja Ribeiro16.
Abstract
Plant-based compounds are an option to explore and perhaps overcome the limitations of current antitumor treatments. Annona coriacea Mart. is a plant with a broad spectrum of biological activities, but its antitumor activity is still unclear. The purpose of our study was to determine the effects of A. coriacea fractions on a panel of cervical cancer cell lines and a normal keratinocyte cell line. The antitumor effect was investigated in vitro by viability assays, cell cycle, apoptosis, migration, and invasion assays. Intracellular signaling was assessed by Western blot, and major compounds were identified by mass spectrometry. All fractions exhibited a cytotoxic effect on cisplatin-resistant cell lines, SiHa and HeLa. C3 and C5 were significantly more cytotoxic and selective than cisplatin in SiHa and Hela cells. However, in CaSki, a cisplatin-sensitive cell line, the compounds did not demonstrate higher cytotoxicity when compared with cisplatin. Alkaloids and acetogenins were the main compounds identified in the fractions. These fractions also markedly decreased cell proliferation with p21 increase and cell cycle arrest in G2/M. These effects were accompanied by an increase of H2AX phosphorylation levels and DNA damage index. In addition, fractions C3 and C5 promoted p62 accumulation and decrease of LC3II, as well as acid vesicle levels, indicating the inhibition of autophagic flow. These findings suggest that A. coriacea fractions may become effective antineoplastic drugs and highlight the autophagy inhibition properties of these fractions in sensitizing cervical cancer cells to treatment.Entities:
Keywords: autophagy; cell cycle arrest; cervical cancer; natural compounds
Mesh:
Substances:
Year: 2019 PMID: 31683835 PMCID: PMC6864525 DOI: 10.3390/molecules24213963
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Proposed structures by ESI (-) FT-ICR MS for the main molecules in C3 and C5 fractions from Annona coriacea.
|
|
| Error (ppm) | DBE | [M-H]− | Proposed Compound | Reference |
|---|---|---|---|---|---|---|
| 255.2332 | 255.23324 | −1.12 | 1 | [C16H32O2–H+]− | palmitic acid | Chen et al., 2016 |
| 281.24881 | 281.24886 | 0.92 | 2 | [C18H34O2–H+]− | oleic acid | Chen et al., 2016 |
| 595.45815 | 595.45822 | −0.49 | 4 | [C35H64O7–H+]− | asitrocinone | Adewole e Ojewole et al., 2008 |
| 595.45838 | 595.45845 | −0.87 | 4 | [C35H64O7–H+]− | annonacin | Alkofahi et al., 1988 |
| 609.43885 | 609.43893 | −2.85 | 5 | [C35H62O8–H+]− | trilobalicin | He et al., 1997 |
| 611.45312 | 611.45314 | −0.49 | 4 | [C35H64O8–H+]− | annomuricin E | Kim et al., 1998 |
| 621.4742 | 621.4743 | −1.17 | 5 | [C37H66O7–H+]− | asimicin | Ye et al., 1996 |
| 621.47413 | 621.47418 | −0.96 | 5 | [C37H66O7–H+]− | bullatacin | Morre et al., 1995 |
| 627.4483 | 627.44832 | −0.9 | 4 | [C35H64O9–H+]− | annohexocin | Moghadamtousi et al., 2015 |
| 627.44823 | 627.44828 | −0.83 | 4 | [C35H64O9–H+]− | murihexocin | Kim et al., 1998 |
| 635.4540 | 635.4542 | −2.14 | 6 | [C37H64O8–H+]− | goniotriocin | Alali et al., 1999 |
| 637.46921 | 637.46927 | −1.22 | 5 | [C37H66O8–H+]− | bullatalicinone | Hui et al., 1991 |
| 637.46905 | 637.46914 | −1.02 | 5 | [C37H66O8–H+]− | annoglaucin | Bermejo et al., 2005 |
| 641.42889 | 641.42895 | −1.34 | 4 | [C35H64O10–H+]− | coriaheptocin B/A | Formagio et al., 2015 |
| 651.44943 | 651.44949 | −2.65 | 6 | [C35H64O10–H+]− | ginsenoside Rh5 | Vamanu, 2014 |
| 653.46442 | 653.46444 | −1.58 | 5 | [C37H66O9–H+]− | salzmanolin | Queiroz et al., 2003 |
| 669.46005 | 669.4601 | −1.22 | 6 | [C37H68O10–H+]− | annoheptocin A | Meneses Da Silva et al., 1998 |
| 671.47569 | 671.47575 | −1 | 6 | [C37H68O10–H+]− | annoheptocin B | Meneses Da Silva et al., 1998 |
| 763.47932 | 763.47939 | −0.83 | 12 | [C39H70O5–H]− | squamocin glycosilated | Jamkhande e Wattamwar, 2015 |
DBE: Double bond equivalent; m/z: mass-to-charge ratio.
IC50 values for A. coriacea compounds and cisplatin in cervical cancer cell lines.
| IC50 Value (Mean ± SD) µg/mL | ||||||||
|---|---|---|---|---|---|---|---|---|
| Cell Line | C1 | C2 | C3 | C4 | C5 | C6 | C7 | Cisplatin |
| CaSki | 17.8 ± 2.8 | ND | 6.5 ± 1.8 | ND | 3.6 ± 0.9 | 11.7 ± 2.2 | 21.4 ± 3.3 | 1.05 ± 1.2 |
| HeLa | 12.2 ± 1.5 | ND | 6.6 ± 1.2 | ND | 4.1 ± 0.4 | 12.9 ± 1.9 | 12.3 ± 0.83 | 13.6 ± 0.44 |
| SiHa | 16.1 ± 2.7 | ND | 8.7 ± 1.3 | ND | 5.1 ± 0.6 | 12.6 ± 1.6 | 12.7 ± 1.3 | 15.5 ± 0.93 |
ND: Not determined; C1: Ethanolic extract; C2: Hexane fraction; C3: Ethyl acetate fraction; C4: Hidroalcoholic fraction; C5: Fraction enriched in acetogenin; C6: Neutral dichloromethane fraction obtained from acid-base extraction; C7: Dichloromethane fraction enriched in alkaloids.
IC50 values and selectivity index for the C3 and C5 fractions of cisplatin to tumor cells as compared with HaCaT.
| IC50 Value (Mean ± SD) µg/mL and SI ª | ||||||
|---|---|---|---|---|---|---|
| Cell Line | C3 | C5 | Cisplatin | SIC3 | SIC5 | SI Cisplatin |
| CaSki | 6.5 ± 1.8 | 3.6 ± 0.9 | 1.05 ± 1.2 | 1.57 | 3.72 | 4.57 |
| HeLa | 6.6 ± 1.2 | 4.1 ± 0.4 | 13.6 ± 0.44 | 1.55 | 3.27 | 0.35 |
| SiHa | 8.7 ± 1.3 | 5.1 ± 0.6 | 15.5 ±0.93 | 1.17 | 2.63 | 0.31 |
| HaCat | 10.2 ± 2.4 | 13.4 ± 1.0 | 4.8 ± 1.3 | R | R | R |
a Selectivity index is the ratio of the IC50 values of the treatments on HaCaT cells to those in the cancer cell lines. SI: Selectivity index; C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; R: Reference cell line.
Figure 1Cytotoxicity in SiHa cells. (A) Cell viability measured after 24 h of exposure in SiHa cells. (B) Cell cytotoxicity measured after 24 h of exposure in SiHa cells. There was an increase in cytotoxicity and a decrease in viability in a dose-dependent manner (p < 0.0001). C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin. *** Indicates a statistical difference between groups. UFR: Relative unit of fluorescence.
Figure 2Cell proliferation and invasion upon C3 and C5 treatment (5µg/mL) in SiHa cells (A) Western blotting of phospho-AKT (protein kinase B) upon C3 and C5 treatment. (B) Number of colonies in the soft agar assay performed for 45 days. (C) BrdU incorporation after C3 and C5 treatment (p < 0.0001) in SiHa cells. (D) Densitometry of p-AKT. (E) Invasion inhibition through C3 and C5 treatments in SiHa cells. (F) Percentage of invasion cells in SiHa cells (*** p < 0.0001; * p < 0.05). * Indicates statistical difference between the treatments). C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin.
Figure 3Cell cycle alterations in SiHa cells after exposure to C3 and C5 compounds (A) Western blot of p21 in SiHa cells upon C3, C5, and cisplatin treatments. (B) Densitometry of p21. (C) Cell cycle profile in SiHa cells. (D) Cell cycle phase distribution after treatment with C3 and C5. (*** p < 0.0001; * p < 0.05). C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin; DMSO: dimethylsulfoxide.
Figure 4Apoptosis evaluation in SiHa cells upon C3 and C5 compounds. (A) Western blot of PARP (Poly (ADP-ribose) polymerase), caspase 3, and H2AX (H2A histone family member X) proteins (B) Flow cytometry for SiHa cells. (C) Comparison of apoptotic cells upon C3 and C5 treatment. There was a significant increase for cells in apoptosis only for cisplatin (CIS) * p = 0.0282 (D) Depolarization of the mitochondrial membrane after treatment with C3 and C5 and cisplatin in the SiHa cell line. C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin; DMM: Depolarized mitochondrial membrane; PMM: Polarized mitochondrial membrane. p < 0.05). C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin.
Figure 5DNA damage evaluation in HeLa cells upon C3 and C5 compounds. (A) Genotoxic damage induced by C3. (B) Genotoxic damage induced by C5. Data are representative of three experiments. Error bars represent SD. C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin; C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin; MMS: Methyl methane sulphonate, DMSO: dimethylsulfoxide. *** p < 0.0001; ** p < 0.01, * p < 0.05).
Figure 6Analysis of the involvement of A. coriacea fractions in autophagy. (A) Analysis of the expression of proteins involved in the autophagic flux in SiHa cells. (B) Densitometry of p62. (C) Densitometry of LC3 B/A (Microtubule-associated protein 1A/1B-light chain 3). (D) Acridine orange staining in SiHa cells. There was a reduction in the percentage of formation of acid vesicles, evidenced by a reduction of the fluorescent green signal after treatment with the fractions (p < 0.05). HBSS: Hank’s balanced salt solution; EBSS: Earle’s balanced salt solution; C3: Ethyl acetate fraction; C5: Fraction enriched in acetogenin; Cis: cisplatin. BAF: Bafilomycin.